Vivani Medical Q1 net loss widens as operating costs rise

Vivani Medical

13/05/2026 21:18

Overview

Biopharmaceutical implant developer posted Q1 net loss of $6.8 mln, wider than last year

Operating expenses for Q1 rose 4% yr/yr due to higher clinical and development costs

Company expects $28 mln in cash and commitments to fund operations through H1 2027

Outlook

Vivani expects to initiate Phase 1 SLIM-1 study of NPM-139 in mid-2026

Company anticipates top-line SLIM-1 results by end of 2026

Vivani expects current cash and commitments to fund operations through H1 2027

Result Drivers

R&D SPENDING - Higher clinical trial and development expenses drove a 4% increase in operating costs in Q1

ADMINISTRATIVE COSTS - General and administrative expenses rose 4% yr/yr, mainly due to increased professional services fees

LOWER OTHER INCOME - Decrease in other income due to lower interest income and write-off related to closure of Switzerland subsidiary

Company press release: ID:nGNX30y5fs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$6.78 mln
Q1 Income from Operations
-$6.82 mln
Q1 Operating Expenses
$6.82 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Vivani Medical Inc is $5.25, about 360.5% above its May 12 closing price of $1.14

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)